Related Experiment Video
Updated: May 17, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
EGFR mutation status in brain metastases of non-small cell lung carcinoma
Fanny Burel-Vandenbos1, Damien Ambrosetti, Michael Coutts
1Department of Pathology, University Hospital of Nice, Nice, France. burel-vandenbos.f@chu-nice.fr
Abstract:
Brain metastases are a frequent and grave complication of non-small cell lung carcinoma (NSCLC). The prognosis is generally poor, despite standard therapy based on surgery and radiotherapy. A degree of understanding of the molecular basis of tumors has led to the development of targeted agents with promising initial findings for the treatment of NSCLC. EGFR mutations have been identified which are associated with significant sensitivity to EGFR tyrosine kinase inhibitors (TKI) and correlate with improved outcome in patients with NSCLC who are treated with these agents. The adoption of treatment tailored to the genetic make-up of individual tumors could lead to substantial therapeutic improvements, and such targeted therapy might be considered as a therapeutic option for brain metastases in the future. We review current knowledge about EGFR mutation status in the specific context of brain metastasis: its association with the response of brain metastases to TKI, its prevalence in brain metastases, and the correlation between mutation status in metastases as compared to the corresponding primary lung carcinoma.
Insights
Epidermal Growth Factor Receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) brain metastases are key to targeted therapy. Understanding EGFR status in brain metastases can improve patient outcomes with tyrosine kinase inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Brain metastases are a severe complication of non-small cell lung carcinoma (NSCLC), often with a poor prognosis despite standard treatments.
- Advances in understanding tumor molecular biology have led to targeted therapies for NSCLC.
- Epidermal Growth Factor Receptor (EGFR) mutations are linked to sensitivity to EGFR tyrosine kinase inhibitors (TKIs), improving outcomes.
Purpose of the Study:
- To review current knowledge on EGFR mutation status in NSCLC brain metastases.
- To examine the association between EGFR mutation status and response to TKIs in brain metastases.
- To determine the prevalence of EGFR mutations in brain metastases and compare it to primary tumors.
Main Methods:
- Literature review of studies investigating EGFR mutation status in NSCLC brain metastases.
- Analysis of data correlating EGFR mutation status with TKI treatment response.
- Comparison of EGFR mutation prevalence between primary NSCLC and corresponding brain metastases.
Main Results:
- EGFR mutations are associated with significant sensitivity to EGFR TKIs.
- EGFR mutation status in brain metastases influences treatment response.
- Prevalence and correlation of EGFR mutations between primary tumors and metastases are critical for treatment decisions.
Conclusions:
- Targeted therapy based on EGFR mutation status holds promise for treating NSCLC brain metastases.
- Tailoring treatment to the genetic profile of individual tumors can lead to substantial therapeutic improvements.
- EGFR mutation status is a crucial factor in considering targeted therapy for brain metastases.
